Volume 6, Issue 4

Clinical Insight: Engaging PWID in HCV Care

In this issue:

People who inject drugs (PWID) comprise a rapidly growing population of HCV-infected people who have historically been difficult to reach and treat. But without engagement in HCV care, PWID will continue to transmit the virus and impede efforts for hepatitis C eradication.

In this issue, Dr. Arthur Kim from Massachusetts General Hospital and Harvard Medical School provides a clinical perspective on identifying and overcoming the barriers that prevent PWID from effectively receiving HCV treatment.

Learning objective:

• Describe the outcomes of HCV treatment with direct-acting antivirals (DAAs) in persons with recent injection drug use.

• Identify barriers to the treatment of HCV for people who inject drugs.


Arthur Y. Kim, MD
Arthur Y. Kim, MD

Associate Professor of Medicine
Harvard Medical School
Director, Viral Hepatitis Clinic
Division of Infectious Diseases
Massachusetts General Hospital
Boston, Massachusetts

Program Directors:

Mark S. Sulkowski, MD

Professor of Medicine
Division of Infectious Diseases
Medical Director, Viral Hepatitis Center
Divisions of Infectious Diseases and Gastroenterology and Hepatology
Johns Hopkins School of Medicine
Baltimore, Maryland

Raymond T. Chung, MD

Director of Hepatology and Liver Center
Vice Chief, Gastroenterology
Kevin and Polly Maroni Research Scholar
Massachusetts General Hospital
Harvard Medical School
Boston, Massachusetts

Taryn Haselhuhn, BA, BSN, MSN, CRNP

The Johns Hopkins Hospital
​Baltimore, Maryland

Length of activity:

0.5 hour Physicians
0.5 contact hour Nurses

Launch date: December 28, 2018
Expiration date: December 27, 2020